Clinical Trial

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Study acronym: SPICE-AF
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-28.
Trial Details
NCT Number NCT07389941
Lead Sponsor University of Luebeck
Conditions Atrial Fibrillation (AF)
Enrollment 240 participants
Start Date 2026-10
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-11